¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-16

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-16
±³À°ÀÏÀÚ : 2022-09-16
±³À°Àå¼Ò : ¼­¿ï ¹é¹ü±è±¸±â³ä°ü ÄÁº¥¼ÇȦ ¹× ´ëȸÀǽǠ 
±³À°ÁÖÁ¦ : 2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ
´ã´çÀÚ : À̼¼Àº
¿¬¶ôó : 02-784-2742  
À̸ÞÀÏ : secretariat@kcnp.or.kr      
±³À°Á¾·ù : Á¤½Å°Ç°­ÀÇÇаú      
Âü¼®¿¹»óÀοø : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 13 ½Ã°£ 30ºÐ  
¼¼ºÎ¼ö°­·á : 90,000¿ø      
ºñ°í »çÀüµî·Ïºñ Æò»ýȸ¿ø ¸éÁ¦/Á¤È¸¿ø 60,000¿ø/ºñȸ¿ø 70,000¿ø/ÁØȸ¿ø ¹× ±âŸ 40,000¿ø/´çÀϵî·Ïºñ Æò»ýȸ¿ø 10,000¿ø/Á¤È¸¿ø 80,000¿ø/ºñȸ¿ø 90,000¿ø/ÁØȸ¿ø ¹× ±âŸ 60,000¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 09:30~09:55 Aducanumab for dementia  ¼­½Â¿Ï(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 09:55~10:20 TAAR1 agonist for schizophrenia  ¾çÂù¸ð(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 10:20~10:40 Orexin and daridorexant for sleep disorder  ¾öÀ¯Çö(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ09:30~09:55 Childbearing and pregnancy  ±èµµÇö(´Ü±¹ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ09:55~10:20 Liver disease  ±è¿øÇü(ÀÎÇÏÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ10:20~10:40 Renal disease  ½Åö¹Î(°í·ÁÀÇ´ë) 
È޽Ġ09-16  10:40~10:55   () 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 10:55~11:20 History of psychedelics: Ancient use  È«Á¤¿Ï(Àͻ꺴¿ø) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 11:20~11:45 The psychedelic renaissance and the prohibition in 20C  Àå½ÂÈ£(¿ø±¤ÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 11:45~12:10 Current researches and the future of psychedelics  ¿Õ¼º¹Î(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ10:55~11:20 Biological mechanism of neural plasticity and neurogenesis  ÀÌÁ¤±¸(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ11:20~11:45 Psychopharmacology of neural plasticity and neurogenesis  ¼ºÇü¸ð(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ11:45~12:10 Non-psychopharmacological approach of neural plasticity and neurogenesis  ±è³«¿µ(°è¿äº´¿ø) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 12:10~12:40 Is Zyprexa beneficial treatment for bipolar disorder  ¼­Á¤¼®(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 12:40~13:10 Role of Zyprexa in the treatment of schizophrenia  ¹ÚÀÏÈ£(°¡Å縯°üµ¿ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ12:10~12:40 MDD with mixed features: How to recognition and management with Aripiprazole in real clinical setting  Á¤¿µÀº(Á¦ÁÖÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ12:40~13:10 Optimizing diagnosis and treatment for MDD with anxious distress  ½ÉÀÎÈñ(µ¿³²±Ç¿øÀÚ·ÂÀÇÇпø) 
È޽Ġ09-16  13:10~13:30   () 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 13:30~13:55 Clinical guideline for depressive disorder  ¿ì¿µ¼·(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 13:55~14:20 Clinical guideline for bipolar disorder  Á¤¸íÈÆ(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 14:20~14:40 Clinical guideline for schizophrenia  ÀÌÁ¤¼®(±¹¹Î°Ç°­º¸ÇèÀϻ꺴¿ø) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ13:30~13:55 Cognitive decline in schizophrenia and its relation with dementia  ¹Ú¼º¿ë(°è¿äº´¿ø) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ13:55~14:20 Polypharmacy in treating schizophrenia: Pros and cons  °­¿ø¼·(°æÈñÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ14:20~14:40 Recent findings of tardive dyskinesia  ÀÌÁß¼±(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 14:40~15:10 ADHD Ä¡·á¾à¹°·Î dextroamphetamineÀÇ ±¹³» µµÀÔÀº ÇÊ¿äÇÑ°¡?  ½É¼¼ÈÆ/Àå¿ÁÁø(¼øõÇâÀÇ´ë/±¹¸³ºÎ°îº´¿ø) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 15:10~15:40 Telepsychiatry, Çã¿ëÇØ¾ß Çϳª?  Á¤Çö°­/ÀÓÀº¼º(°í·ÁÀÇ´ë/½Å¼¼°èÈ¿º´¿ø) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ14:40~15:10 What and why PCT and SDM?  ¹Ú¿µ¹Î(ÀÎÁ¦ÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ15:10~15:40 How to practice PCT in psychiatry  À̹®¼ö(°í·ÁÀÇ´ë) 
È޽Ġ09-16  15:40~15:50   () 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 15:50~16:15 Pathophysiology of hyperprolactinemia  Á¤Çý°æ(°í·ÁÀÇ´ë »êºÎÀΰú) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 16:15~16:40 Endocrinological adverse effect of hyperprolactinemia  ±èÇý¸®(¼­Ãʼº¸ð Á¤½Å°Ç°­ÀÇÇаú) 
±³À°½Ã°£ 09-16 ÄÁº¥¼ÇȦ 16:40~17:00 Clinical guideline for AAP-induced hyperprolactinemia  ±è¼±¹Ì(Áß¾ÓÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ15:50~16:15 Mobile digital technologies in monitoring mental disorders  ¹éÁöÇö(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ16:15~16:40 Mobile digital technologies in treating mental disorders  ÇãÁö¿ø(°í·Á´ë ½É¸®Çаú) 
±³À°½Ã°£ 09-16 ´ëȸÀǽǠ16:40~17:00 Á¤½Å°Ç°­ÀÇÇаú Áø·á¿¡¼­ÀÇ wearable deviceÀÇ È°¿ë  ÀüÈ«Áø(¼º±Õ°üÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2022³â ´ëÇÑÁ¤½Å¾à¹°ÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2022-09-16""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û (¿Â¶óÀÎ)2022³â Á¦ 12ȸ ¼­¿ï¾Æ»êº´¿ø ¾Ë·¹¸£±âÁúȯ ¿ªÇнÉÆ÷Áö¾ö : 2022-09-16
´ÙÀ½±Û ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ) ¾È°ú ±Ý¿äÁý´ãȸ(¾È±¸¿îµ¿Àå¾Ö ȯÀÚ¿¡¼­ÀÇ ´«²¨Ç®Ã³ÁüÀÇ Ä¡·á) : 2022-09-16
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20893 ¼­¿ï ´ëÇѳúÁ¹ÁßÇÐȸ 6¿ù º¸¼ö±³À° : 2024-06-30 0 105 2024-05-27
20892 ¼­¿ï (¿Â¶óÀÎ)Á¦22Â÷ ¼­¿ïƯº°½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-30 0 5 2024-05-27
20891 °æ±â (¿Â¶óÀÎ)Á¦21Â÷ °æ±âµµÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-30 0 5 2024-05-27
20890 Àü³² 2024³â ´ëÇÑ´ëÀåÇ×¹®ÇÐȸ ¿¬¼ö°­Á : 2024-06-30 0 5 2024-05-27
20889 Ãæ³² ´ëÇÑÁ¤Çü¿Ü°úÃÊÀ½ÆÄÇÐȸ - Á¦19Â÷ Ãá°èÇмú´ëȸ ¹× Á¦38Â÷ ±Ù°ñ°Ý°è ÃÊÀ½ÆÄ¿öÅ©¼¥ (Basic Course) : 2024-06-30 0 1 2024-05-27
20888 ºÎ»ê Á¦3ȸ ´ëÇÑÅõ¼®Çùȸ ºÎ»êÁöȸ ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20887 ¼­¿ï Çѱ¹ÁöÁú¤ýµ¿¸Æ°æÈ­ÇÐȸ Á¦7ȸ A to Z (Atherosclerosis to Zero) ¿¬¼ö°­Á ÇÁ·Î±×·¥ : 2024-06-29 0 1 2024-05-27
20886 °æ±â 2024³âµµ ³²¾çÁÖ½ÃÀÇ»çȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20885 ¼­¿ï (¿Â¶óÀÎ)Á¦14ȸ ´ëÇÑ°¨¿°ÇÐȸ Æò»ý±³À° ÇÁ·Î±×·¥ °¨¿°Áúȯ ÃÖ½ÅÁö°ß : 2024-06-29 0 1 2024-05-27
20884 ¼­¿ï Á¦24Â÷ ´ëÇѽÅÀåÇÐȸ ½ÅÀ̽Ŀ¬±¸È¸ ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20883 ¼­¿ï 2024 ¼±Ãµ¼º Ⱦ°æ¸· Å»Àå ÄÚȣƮ (K-CDH) ±³À°¼¼¹Ì³ª : 2024-06-29 0 1 2024-05-27
20882 ¼­¿ï 2024 ¿©¼º½ÉÀåÁúȯ¿¬±¸È¸ ÇÏ°è ½ÉÆ÷Áö¾ö : 2024-06-29 0 1 2024-05-27
20881 °­¿ø 2024 ³âµµ Á¤Çü¿Ü°úÇб³½Ç °³¿øÀÇ¿¬¼ö°­Á : 2024-06-29 0 1 2024-05-27
20880 ¼­¿ï (¿Â¶óÀÎ) 2024 ¸¶Æ÷±¸ÀÇ»çȸ ¿Â¶óÀÎ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
20879 ¼­¿ï Á¦10ȸ ¿ëºÀÀÇÇÐȸ Çмú´ëȸ : 2024-06-29 0 1 2024-05-27
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷